mTOR inhibitors.
University of Chicago, USA.
Ezra
E
Cohen
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases
D000903:Antibiotics, Antineoplastic; D004791:Enzyme Inhibitors; C401859:temsirolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus